Atara Biotherapeutics, Inc. short interest in 2024
In 2024, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 7.19% of shares outstanding on 12 Jan 2024 to 9.26% on 31 Dec 2024, a change of +2.07 percentage points. The year's high was 13.00% on 15 Oct 2024 and its low 7.19% on 12 Jan 2024, averaging 9.65% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.71 days on 30 Apr 2024. Full history: Atara Biotherapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 7.19% (12 Jan 2024)
- End of year
- 9.26% (31 Dec 2024)
- Change
- +2.07 pp
- High
- 13.00% (15 Oct 2024)
- Low
- 7.19% (12 Jan 2024)
- Average
- 9.65%
- Highest days to cover
- 13.71 (30 Apr 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 7.19% | 2.41 | |
| 31 Jan 2024 | 7.39% | 4.20 | |
| 15 Feb 2024 | 10.67% | 1.52 | |
| 29 Feb 2024 | 9.95% | 5.16 | |
| 15 Mar 2024 | 10.82% | 3.60 | |
| 28 Mar 2024 | 9.41% | 8.60 | 10-K filed, results (8-K) |
| 15 Apr 2024 | 9.59% | 10.10 | |
| 30 Apr 2024 | 9.95% | 13.71 | |
| 15 May 2024 | 9.73% | 7.62 | 10-Q filed, results (8-K) |
| 31 May 2024 | 9.44% | 9.44 | |
| 14 Jun 2024 | 9.03% | 10.96 | |
| 15 Aug 2024 | 7.70% | 6.45 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 8.35% | 6.84 | |
| 13 Sep 2024 | 9.42% | 1.18 | |
| 30 Sep 2024 | 10.71% | 5.36 | |
| 15 Oct 2024 | 13.00% | 8.25 | |
| 31 Oct 2024 | 12.95% | 6.33 | |
| 15 Nov 2024 | 9.02% | 2.93 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 9.44% | 6.81 | |
| 13 Dec 2024 | 9.57% | 6.85 | |
| 31 Dec 2024 | 9.26% | 5.62 |
See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.